Entering text into the input field will update the search result below

Cel-Sci late-stage Multikine study in head and neck cancer to continue

Apr. 23, 2020 11:28 AM ETCEL-SCI Corporation (CVM) StockBy: Douglas W. House, SA News Editor11 Comments
  • Cel-Sci (NYSE:CVM +3.0%) announces the completion of an interim analysis by the independent Data Monitoring Committee of its Phase 3 clinical trial evaluating Multikine immunotherapy in head and neck cancer patients.
  • The committee agreed that the study should continue without modification.
  • The primary endpoint of the 928-subject trial is overall survival at year 3 versus standard-of-care surgical resection followed by radiation therapy or radiochemotherapy. The survival benefit will be based on the occurrence of 298 events (deaths) between the two treatment arms.

Recommended For You

About CVM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVM--
CEL-SCI Corporation